Pharmanovia

Global pharmaceuticals company Pharmanovia wanted to drive a corporate affairs-led campaign in which it would communicate with key stakeholders around the challenges and achievements of its international sustainability work.

The UK-founded company, which focuses on the commercialisation of novel medicines and revitalises, extends and expands the lifecycle of established medicine, began the recording of its ESG journey with its inaugural sustainability report. It followed up on this project one year later with a second report which recorded progress in a number of key areas and initiatives as it sought to make good on its pledges to cut greenhouse gas emissions throughout its entire value chain by 2030.

As well as outlining projects to help communities in international jurisdictions where it has operations, challenging staff with annual ESG targets and establishing a strong sustainability framework across the business, Pharmanovia wanted to take a leadership stance on the reduction of Scope 3 (supply chain) emissions.

This followed one industry report which revealed that just 16 of the 500 pharma companies polled measured their Scope 3 emissions.

The PHA Group worked closely with Pharmanovia to provide communications support around the inaugural report. We then developed communications strategies to support the promotion of the initial report and its follow-up, highlighting the company’s proactive, transparent approach to its ESG journey.

Following a phase of market analysis, our strategy focused on storytelling around key initiatives, highlighting critical points in the reports for news releases and briefings with key journalists. One important strand of activity was to provide detail to media that as part of its own response around Scope 3 emissions, Pharmanovia had launched a pilot project to switch its freight operations, for the movement of its global supplies and products, from air to sea.

We were able to follow up with a media campaign around the results of this initiative in the second report.

As well as news briefings and the commissioning of a global media relations programme, we successfully positioned Pharmanovia as thought leaders, working closely with key spokespeople to place in key media expertly curated opinion pieces containing key messages and arguments.

We also advised the firm to leverage its strong LinkedIn presence and utilised the platform’s appetite for long-form content with Op Ed articles exploring pharma’s relationship with ESG.